Axcella Health is a clinical-stage biotechnology company focused on pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator compositions. Co.'s pipeline includes its main therapeutic candidates: AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy; and AXA1125 for non-alcoholic steatohepatitis. AXA1665 is a composition of eight amino acids and derivatives. AXA1125 is a product candidate that contains six amino acids and derivatives. Both are designed to target multiple metabolic pathways intersecting key organ systems (liver, muscle and gut) key to support and maintain liver health. The AXLA stock yearly return is shown above.
The yearly return on the AXLA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AXLA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|